AKT1 and breast cancer: HCT116 cells harbor the H1047R PIK3CA-activating mutation, and the addition of BYL719 decreased AKT phosphorylation but did not decrease mTORC1 signaling, mimicking the phenotype observed in BYL719-resistant breast cancer cell lines.